NEW DELHI: Claris Life sciences on Tuesday said it has received US food and drug administration (USFDA) nod for selling three different injectable products in the US market.
Ahmedabad-based company has got the approval from USFDA for selling Ciproflaxacin and Metronidazole, the anti infective compounds and Ondansetron, an anti vomiting drug in the US market.
The successful launch of these products in the market would provide a major fillip to the company's US strategy and overall business growth, the company said in a statement.
"After USFDA acceptance of our facility, this is perhaps one of the most important milestones, we have achieved as far as US operation of the company," Mr Arjun Handa, COO of Claris said.
Claris is an international Life science company operating in critical care segment, with special focus on injectables. - PTI - April 2008
|
